Core Insights - The latest episode of The BioMedWire Podcast features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd., discussing the company's innovative approach in the biopharmaceutical sector [2][3] - Scinai Immunotherapeutics is focused on developing biological therapeutic products targeting inflammation and immunology, utilizing a unique technology of VHH single domain antibodies derived from alpacas [3][5] - The company employs a de-risking strategy by targeting molecular areas already explored by other manufacturers, aiming to address significant unmet medical needs in patient populations [3] Company Overview - Scinai Immunotherapeutics Ltd. operates two business units: one dedicated to the development of biological therapeutic products and the other providing CDMO services for early-stage biotech projects [5] - The company’s innovative pipeline includes nanosized VHH antibodies (NanoAbs) designed to target diseases with large unmet medical needs [5] Podcast and Distribution - The BioMedWire Podcast aims to connect public companies with the investment community through specialized content distribution [1][4] - IBN has over 18 years of experience in providing corporate messaging solutions to more than 500 public and private companies, leveraging a robust network of brands and followers [4][6]
IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.